Phase I Corporate Sponsor Events

Roundtable Discussions:

Monday, February 3│ 5:15 pm – 6:30 pm │Park West Foyer

Vapotherm Roundtable:

Hosts: Joe Army, President and CEO
Jill Dooling, Vice President of Strategic Accounts
John Walsh, Area Vice President, Clinical

Title: Take a Breath for EMF

Try Hi-VNI® Technology and help raise money for the Emergency Medicine Foundation (EMF).  For each Emergency Medicine Provider that tries on the therapy, Vapotherm will donate $10 to the Emergency Medicine Foundation ($20 for every Emergency Medicine Resident).

Vapotherm Hi-VNI® Technology is Mask-Free NIV™ for spontaneously breathing patients.

  • Provides fast, effective respiratory support for the patient that arrives in the Emergency Department in undifferentiated respiratory distress, including hypercapnia, hypoxemia and dyspnea.
  • Reduces the risk and care complexities associated with mask therapies.
  • Trusted by over 1,250 US Hospitals and backed by top-tier clinical evidence.

 

Tuesday, February 4│ 5:15 pm – 7:00 pm │Hunters Lounge

Intrigma Roundtable:

Hosts: Tal Eidelberg, CEO, Intrigma
Dr. Vinh Le, CEO, UBQ

Title: Systematic and Rigorous Approach to Emergency Department Demand Capacity Management

Scheduling alignment and care ownership matter in demand capacity planning in Emergency Departments. Mismatched demand and capacity lead to poor care, low morale and dismal financial performance. Until now, there has been no effective workforce planning and process design that can proactively plan for demand and flex capacity in real-time to optimize care and financial performance. Tal Eidelberg, CEO of Intrigma, along with Dr. Vinh Le, CEO of UBQ, presents a systematic and rigorous approach to Emergency Department demand capacity management.

 

Wednesday, February 5│ 5:00 pm – 6:30 pm │Hunters Lounge

Fisher & Paykel Healthcare Roundtable:

Hosts: Jason Kirkness, Clinical Affairs Director
Courtney Shiels, Clinical Affairs Specialist
Chris Hutchinson, Senior Market Development Manager

Title: Nasal High Flow Therapy in Respiratory Distress 

Discussion about current practice and approaches to improve clinical outcomes, patient comfort and bed throughput in the emergency department using Nasal High Flow Therapy for patients in Respiratory Distress:

  • Recognize the appropriate patient populations for application of nasal high flow therapy versus nasal oxygen cannula or non-invasive ventilation.
  • Stabilize the patient using an evidence-based algorithm for initiation, monitoring, and weaning to decrease escalation.
  • Mobilize the patient to the floor, ICU, or ambulance with transport capability and growing use of nasal high flow therapy throughout the hospital setting.

 

Thursday, February 6│ 5:30 pm – 7:00 pm │Hunters Lounge

Portola Pharmaceuticals Roundtable:

Hosts: Jody Thompson, Director
Eva Solis, Director
Stefan Stanko, Area Director
Julz Lowenberg, Manager

Title: Direct Oral Anticoagulation Reversal Strategies – Management of Life-threatening Bleeds in the Emergency Department 

 

Complimentary Dinner and Educational Presentations

Vapotherm: Tuesday, February 4 │ 7:00 pm – 8:30 pm │ Park West Ballroom E

Title: Vapotherm Hi-VNI® Technology: No Mask. No Problem. Mask-Free NIV™ for Spontaneously Breathing Patients

Dr. Adam Hennessey will discuss current research and his clinical practice experience using High-Velocity Nasal Insufflation (HVNI), a mask-free noninvasive ventilation solution for patients in respiratory distress in the Emergency Department, including hypercapnia, hypoxemia and dyspnea.

Presenter: Adam Hennessey, DO, FACEP, Assistant Medical Director of Our Lady of Lourdes Emergency Department in Camden, NJ; Assistant Clinical Professor of Emergency Medicine, Thomas Jefferson University

Pick up a dinner ticket at the EDDA registration table during a break. Seating is limited and tickets are offered on a first-come, first-served basis.

Fisher and Paykel Healthcare: Wednesday, February 5 │ 6:30 pm – 8:00 pm │ Park West Ballroom E

Title: Nasal High Flow in the ED: Reducing Escalation and Improving Mobilization

The presentation will be an engaging and visual dive into practical application of nasal high flow therapy in the Emergency Department.  It will look at the mechanisms and physiological interactions that drive the evidence supporting improved clinical outcomes.  This will be presented along with a hands-on display portion to demonstrate the use and transport capability.  

Learning objectives:

  1. Describe the dose-dependent responses and physiological effects of nasal high flow therapy up to 60 L/min compared to and contrasted with other therapies, including nasal oxygen cannula and NIV.
  2. Identify appropriate patient populations and review validated evidence-based algorithms for deploying nasal high flow therapy, predicting patient success/failure, and improved patient outcomes.
  3. Discuss strategies for successful implementation of nasal high flow therapy throughout the hospital to improve patient throughput, decrease length of stay, and reduce healthcare costs.

Presenter: Coming Soon

Pick up a dinner ticket at the EDDA registration table during a break. Seating is limited and tickets are offered on a first-come, first-served basis.

Portola Pharmaceuticals: Thursday, February 6 │ 7:00 pm – 8:30 pm │ Park West Ballroom E

Title: Andexxa® (coagulation factor Xa (recombinant), inactivated-zhzo)

Dr. Fermann will cover the burden of life-threatening bleeds related to FXa inhibitors and review the indications, mechanism, efficacy and safety of products used for the reversal of FXa inhibitors rivaroxaban and apixaban. 

Presenters: Gregory Fermann, MD, FACC, Executive Vice Chairman, Department of Emergency Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio

Pick up a dinner ticket at the EDDA registration table during a break. Seating is limited and tickets are offered on a first-come, first-served basis.

Deliver Passion

ACEP Directors Academy delivers at the highest level consistently because the passion of the faculty comes through every encounter. It will help anyone be a better EP or EP Director.